|1.||Blaney, Susan M: 3 articles (09/2012 - 01/2005)|
|2.||Hurley, Thomas D: 2 articles (03/2014 - 01/2014)|
|3.||Fishel, Melissa L: 2 articles (03/2014 - 01/2014)|
|4.||Parajuli, Bibek: 2 articles (03/2014 - 01/2014)|
|5.||Packer, Roger: 2 articles (09/2012 - 01/2005)|
|6.||Pollack, Ian F: 2 articles (09/2012 - 01/2005)|
|7.||Kun, Larry: 2 articles (09/2012 - 01/2005)|
|8.||Gajjar, Amar: 2 articles (09/2012 - 01/2005)|
|9.||Heideman, Richard: 2 articles (09/2012 - 01/2005)|
|10.||Phillips, Peter: 2 articles (09/2012 - 01/2005)|
11/01/1989 - "Pharmacological purging with the oxazaphosphorine derivative mafosfamide has been studied extensively, and recent clinical data suggest that purging with mafosfamide may translate into superior remission duration if compared to nonpurged ABMT in acute leukemia. "
01/01/1989 - "Drug-mediated marrow purging: mafosfamide in adult acute leukemia in remission. "
12/01/1999 - "In this study of autotransplantation for acute leukemia using mafosfamide-purged marrow, the stem cell dose used for purging and the intensity of purging were the most important factors predicting outcome."
04/09/1990 - "Biotransformation of mafosfamide in P388 mice leukemia cells: intracellular 31P-NMR studies."
12/01/1999 - "We retrospectively analyzed patients with acute leukemia autografted with marrow purged with mafosfamide after January 1983 in our institution. "
|2.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/01/1993 - "Techniques for pharmacological marrow decontamination, clinical result obtained with ABMT and the efficacy of ABMT with mafosfamide purged marrow in patients with acute myelogenous leukemia are reviewed."
07/01/2002 - "Long-term outcome in acute myelogenous leukemia autografted with mafosfamide-purged marrow in a single institution: adverse events and incidence of secondary myelodysplasia."
12/01/2001 - "Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging."
01/01/1990 - "The analysis of clinical data in terms of disease-free survival (DFS) shows that the "programmed method" gives significantly better results than those obtained using the standard dose of mafosfamide (80% DFS in 18 AL patients vs. 44% in 33 ANLL patients and 33% in 56 ALL patients). "
01/01/1991 - "Autologous marrow transplantation in first remission acute myeloid leukemia using marrow purged with mafosfamide."
07/01/1993 - "Our results indicate that a combination of a conventional chemotherapeutic agent and a tumor-specific antisense oligodeoxynucleotide is highly effective in killing leukemic cells and in sparing a much higher number of normal progenitor cells as compared with high-dose mafosfamide treatment. "
03/21/2014 - "However, sensitivity toward the anti-proliferative effects of mafosfamide is enhanced by treatment with CB29 and its analogue in the tumor cells. "
10/01/1996 - "These were cis-platin and mafosfamide, which are widely used for the management of solid tumors. "
11/01/1989 - "The autograft was incubated with the active CY derivative Mafosfamide (ASTA Werke, Bielefeld, Federal Republic of Germany) to reduce the number of possibly contaminating clonogenic tumor cells. "
01/01/1989 - "In nude mice treatment of the L5222 with low doses of mafosfamide also resulted in surviving animals, however resistance to a second tumor challenge occurred only sporadically. "
|4.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/01/1992 - "Effects of mafosfamide on the clonogenic cells in precursor B acute lymphoblastic leukemia: significance for ex vivo purging of bone marrow."
03/01/1992 - "It, therefore, was the aim of the present study to investigate in a group of patients with acute nonlymphoblastic leukemia (ANLL; n = 19) and acute lymphoblastic leukemia (ALL; n = 19) in complete remission the effect of mafosfamide at the level of adherent blast colony-forming units (blast colony-forming units, CFU-Blast), as well as multipotential (granulocyte erythrocyte macrophage megakaryocyte colony-forming units, CFU-GEMM), erythroid (erythroid burst-forming units, BFU-E), and granulocyte-macrophage (granulocyte-macrophage colony-forming units, CFU-GM) progenitor cells. "
01/01/2002 - "In the group of initial Acute Lymphoblastic Leukemia (ALL) samples, equivalent cytotoxicity values for glufosfamide, 4-HOO-ifosfamide, 4-HOO-cyclophosphamide and mafosfamide were 5.95, 9.92, 4.60 and 3.90 microg/ml, respectively. "
05/01/1994 - "Primary cyclophosphamide-naive clonogenic blasts from 32 patients with newly diagnosed acute lymphoblastic leukemia (ALL) were tested for their in vitro sensitivity to an "activated" cyclophosphamide, viz., mafosfamide, using leukemic progenitor cell (LPC) colony assays. "
05/01/1994 - "Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide."
|5.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/01/1993 - "Successful mafosfamide purging of bone marrow from chronic myelogenous leukemia (CML) cells."
01/01/1990 - "Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. "
01/01/1990 - "We studied the SCE-inducing effect of mafosfamide on leukemic cells of Philadelphia (Ph)-positive chronic myeloid leukemia (CML) as a model for leukemic cells. "
11/04/1989 - "[Bone marrow autograft treated with mafosfamide in the acceleration phase in chronic myeloid leukemia. "
09/01/1994 - "Ten adult patients with Ph-positive chronic myelogenous leukemia (CML) received autologous transplantation using marrow treated ex vivo with mafosfamide. "
|3.||Morphine (MS Contin)
|5.||Asta Z 7557
|6.||Etoposide (VP 16)
|8.||K 76 carboxylic acid
|10.||glucosyl-ifosfamide mustard (glufosfamide)
|1.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|2.||Transplantation (Transplant Recipients)
|3.||Drug Therapy (Chemotherapy)